



## ASX ANNOUNCEMENT

### VivaGel<sup>®</sup> phase 2 study results – Investor conference call

**Melbourne Australia; 3 April 2013** – Starpharma Holdings Limited (ASX: SPL, OTCQX SPHRY) will be hosting an investor conference call to discuss results of the Company's Phase 2 clinical trial for the prevention of recurrent bacterial vaginosis.

The call will be hosted by Starpharma Chief Executive Officer Dr Jackie Fairley. It will also be available via webstream.

#### Conference call times

<b>Melbourne / Sydney (Australia)</b>	<b>Thursday, 4 April 2013 at 9:30 AM AEDT UTC+11 hours</b>
San Francisco (US)	Wednesday, 3 April 2013 at 3:30 PM PDT UTC-7 hours
New York (US)	Wednesday, 3 April 2013 at 6:30 PM EDT UTC-4 hours
London (UK)	Wednesday, 3 April 2013 at 11:30 PM BST UTC+1 hour
Hong Kong / Singapore	Thursday, 4 April 2013 at 6:30 AM HKT UTC+8 hours
Corresponding UTC (GMT)	Wednesday, 3 April 2013 at 10:30

**Please quote conference ID: 3188 3659**

#### Australian Participant Dial in details:

Participants can dial either of the numbers below to join the call. You will need to quote the ID provided above.

To ask a question, participants will need to dial “\*1” (star, 1) on their telephone keypad.

Toll: + 61 2 8314 8370 - (can be used if dialing from international location).

Toll-free: 1800 123 296.

#### International Participant Dial In Numbers

These numbers are toll-free dial in numbers for each country listed below. For countries not listed below, the Australian Toll number listed above can be dialed.

To ask a question, participants will need to dial “\*1” (star, 1) on their telephone keypad.

China	4001203085
Hong Kong	800 908 865
India	180030106141

Japan	0120 985 190
New Zealand	0800 452 782
Singapore	800 616 2288
United Kingdom	0808 234 0757
United States	1855 293 1544

### **Web access**

<http://www.openbriefing.com/OB/1039.aspx>

## ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma has announced significant tumour-targeting results in its docetaxel (Taxotere®) program, with animal studies showing its dendrimer-enhanced version of docetaxel to have significantly superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including Nufarm (ASX:NUF) and Makhteshim Agan as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

## FOR FURTHER INFORMATION

### **Media:**

#### **Buchan Consulting**

Rebecca Wilson

Mob: +61 417 382 391

[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Danny Rose

Mob: +61 407 25 00 88

[drose@buchanwe.com.au](mailto:drose@buchanwe.com.au)

### **Starpharma:**

Dr Jackie Fairley, Chief Executive Officer  
+61 3 8532 2704

Ben Rogers, Company Secretary  
[ben.rogers@starpharma.com](mailto:ben.rogers@starpharma.com)

[www.starpharma.com](http://www.starpharma.com)

### **Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could

provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.